Table 3.

Prevalence of HPV types in VIN 1, VIN 2/3, and VIN 3 lesions

YearFirst authornMultitype infections (%)Percentage of specimens testing positive for individual HPV types
Any HPV type*
6111618313335394551525658596668707382
VIN 1(51, 55)
2006Srodon3321.227.315.26.10.03.03.00.00.00.06.13.00.06.16.13.09.13.090.9
2003Logani119.136.49.19.10.09.10.00.00.00.09.10.00.00.00.00.09.10.0100.0
Pooled prevalence4418.229.513.66.80.04.52.30.00.00.06.82.30.04.54.52.39.12.393.2
95% CI, lower18.26.42.30.01.30.40.00.00.02.30.40.01.31.30.43.60.4
95% CI, upper44.226.718.28.015.111.88.08.08.018.211.88.015.115.111.821.211.8
Multitype adjusted4429.212.55.10.02.30.00.00.00.00.00.00.04.52.82.39.10.0
95% CI, lower17.95.71.50.00.40.00.00.00.00.00.00.01.30.60.43.60.0
95% CI, upper43.925.415.98.011.88.08.08.08.08.08.08.015.112.711.821.28.0
VIN 3
2006Srodon3411.80.02.991.25.90.02.95.90.00.02.92.90.00.00.00.02.90.0100.0
2001Carter4699.53.10.077.09.01.08.70.20.01.80.00.80.00.30.00.00.00.00.30.091.5
Pooled prevalence5039.72.80.277.98.70.98.30.60.01.70.20.90.00.20.00.00.20.00.30.092.2
95% CI, lower1.60.074.16.40.46.00.20.00.80.00.40.00.00.00.00.00.00.00.0
95% CI, upper4.91.381.311.82.411.31.70.93.41.32.40.91.30.90.9.30.91.41.0
Multitype adjusted424§0.00.077.76.30.26.30.50.00.70.00.20.00.00.00.00.00.00.00.0
95% CI, lower0.00.073.54.30.04.40.10.00.30.00.00.00.00.00.00.00.00.00.0
95% CI, upper0.90.981.49.01.39.01.70.92.10.91.30.90.90.90.90.90.91.01.0
  • * As determined by consensus PCR primers sensitive to positivity for at least 15 HPV types.

  • Additional data on the type distribution within multitype HPV infections were kindly referred to us for the Srodon et al. study (36). Lesions in these studies containing multiple HPV types were fractionally attributed to individual HPV types as described in Materials and Methods. Based on this method, figures for the attribution of individual HPV types differing from those reported in the table for prevalence were as follows: Srodon et al. VIN 1 (HPV 6, 26.8%; HPV 11, 13.6%; HPV 16, 3.8%; HPV 31, 0.0%; HPV 33, 0.0%; HPV 51, 0.0%; HPV 52, 0.0%; HPV 59, 3.8%; HPV 70, 0.0%), VIN 3 (as reported here); Logani et al. VIN 1 (HPV 51, 0.0%); Carter et al. VIN 3 (HPV 6, 0.0%; HPV 16, 76.5%; HPV 18, 6.8%; HPV 31, 0.3%; HPV 33, 6.6%; HPV 35, 0.0%; HPV 45, 0.8%; HPV 52, 0.3%; HPV 58, 0.0%; HPV 73, 0.0%).

  • Data for additional cases and HPV typing provided by the authors. In the study, HPV testing methods changed over time. Early testing of specimens (n = 79) was conducted for individual HPV types 16 and 35 (HPV testing for types 6/11, 18/45, and 31/33 were combined in single cocktails). Later testing (n = 390) was conducted for a much broader spectrum of individual HPV types. In the table, prevalence data are reported across all specimens for HPV types 16 and 35, whereas only specimens tested during the latter period are included in results for the remaining HPV types as earlier testing for these types individually was not conducted. Only specimens tested during the latter period are included in the multitype adjusted HPV data, as the earlier testing covered <8 HPV types.

  • § n refers to total number of lesions with any HPV typing data. By individual HPV type, number of observations varies depending on the number of types for which data were available within each study.